Eli Lilly and Company (NYSE:LLY) Holdings Boosted by TCI Wealth Advisors Inc.

TCI Wealth Advisors Inc. boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 8.5% during the 4th quarter, HoldingsChannel reports. The firm owned 8,101 shares of the company’s stock after buying an additional 637 shares during the quarter. Eli Lilly and Company accounts for 0.5% of TCI Wealth Advisors Inc.’s investment portfolio, making the stock its 29th biggest holding. TCI Wealth Advisors Inc.’s holdings in Eli Lilly and Company were worth $4,722,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sage Mountain Advisors LLC grew its holdings in shares of Eli Lilly and Company by 5.2% during the 3rd quarter. Sage Mountain Advisors LLC now owns 4,169 shares of the company’s stock valued at $2,239,000 after acquiring an additional 206 shares in the last quarter. Sawyer & Company Inc grew its holdings in shares of Eli Lilly and Company by 0.4% during the 3rd quarter. Sawyer & Company Inc now owns 6,710 shares of the company’s stock valued at $3,604,000 after acquiring an additional 25 shares in the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH grew its holdings in shares of Eli Lilly and Company by 13.1% during the 3rd quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 68,290 shares of the company’s stock valued at $36,681,000 after acquiring an additional 7,894 shares in the last quarter. Vantage Investment Partners LLC grew its holdings in shares of Eli Lilly and Company by 2.2% during the 3rd quarter. Vantage Investment Partners LLC now owns 31,114 shares of the company’s stock valued at $16,712,000 after acquiring an additional 656 shares in the last quarter. Finally, Lathrop Investment Management Corp grew its holdings in shares of Eli Lilly and Company by 1.2% during the 3rd quarter. Lathrop Investment Management Corp now owns 1,476 shares of the company’s stock valued at $793,000 after acquiring an additional 18 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded down $20.94 during mid-day trading on Friday, hitting $734.97. The company had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73. The business’s 50-day simple moving average is $761.06 and its 200-day simple moving average is $672.28. Eli Lilly and Company has a 12 month low of $419.80 and a 12 month high of $800.78. The firm has a market cap of $698.52 billion, a P/E ratio of 108.24, a PEG ratio of 1.46 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter last year, the company earned $1.62 earnings per share. The firm’s revenue was up 26.0% on a year-over-year basis. As a group, analysts predict that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a report on Wednesday, February 21st. Truist Financial upped their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.